Tag

Pembrolizumab

All articles tagged with #pembrolizumab

health1 day ago•5 min saved

Immunotherapy Before Surgery Sparks Three-Year Remission in Bowel Cancer Trial

In the NEOPRISM-CRC trial, 32 patients with stage II/III MMR-deficient/MSI-high bowel cancer received three doses of pembrolizumab before planned surgery. Seventy percent? No—the article states 59% had no signs of disease after pembrolizumab ahead of surgery, and after nearly three years none of the 32 patients have experienced a recurrence, meaning all remained cancer-free. The results suggest neoadjuvant immunotherapy could change treatment for some bowel cancers and possibly reduce chemotherapy needs, though not all patients benefit. Researchers are exploring blood tests and immune profiling to predict responders, while NHS access to such therapy remains under consideration.

via BBC|

#bowel-cancer #cancer-trial #health

health27 days ago•4 min saved

Pre-Surgery Immunotherapy Sparks Long-Term Remission in Colorectal Cancer

In the NEOPRISM-CRC trial, 32 patients with stage II-III MSI-H/MMR-deficient colorectal cancer received up to nine weeks of pembrolizumab before surgery instead of chemo; after ~33 months of follow-up, none have recurred and 59% had no detectable cancer after treatment, a sharp contrast to the typical ~25% recurrence with standard surgery-plus-chemotherapy. The study also linked blood-based tumor DNA clearance and pre-treatment immune profiling to predicting who will respond, suggesting biomarkers to tailor therapy.

via ScienceDaily|

#colorectal-cancer #health #immunotherapy

health28 days ago•6 min saved

Pre-surgery pembrolizumab linked to zero recurrences in a small bowel cancer trial

In a 32-patient trial of stage 2–3 bowel cancer with MMR-deficient/MSI-high tumors, a short course of pembrolizumab before surgery kept all patients cancer-free for nearly three years; early data showed 59% had no signs of cancer at surgery, and long-term follow-up found no recurrences, a result that may surpass standard chemotherapy for this subset but is limited by size and specificity. Researchers also used tumor DNA blood tests to monitor response and aim to predict who will benefit. Presented at AACR 2026; longer follow-up is needed.

via Fox News|

#bowel-cancer #health #immunotherapy

health1 month ago•5 min saved

Pre-Surgery Immunotherapy Sparks Near-Three-Year Cancer-Free Remission in Bowel Cancer

A UK-led NEOPRISM-CRC trial treated stage II/III MMR-deficient/MSI-H bowel cancer with up to nine weeks of pembrolizumab before surgery. After ~33 months of follow-up, none of the 32 patients have recurred, and 59% had no detectable cancer at surgery, suggesting preoperative immunotherapy may provide durable control compared with standard surgery followed by chemotherapy. Researchers are also using personalized blood tests and immune profiling to predict responders and monitor remaining disease.

via SciTechDaily|

#bowel-cancer #clinical-trial #health

science1 month ago•25 min saved

Neoadjuvant Immunotherapy Achieves 100% No-Recurrence in MSI-H Colorectal Cancer Trial

A small NEOPRISM-CRC trial at University College London treated stage II/III colorectal cancers with MSI-H/MMR-deficient tumors using pembrolizumab before surgery. After nearly three years of follow-up, no patient experienced cancer recurrence, suggesting neoadjuvant immunotherapy could spare or reduce chemotherapy for this 10–15% subset of bowel cancers, though larger studies are needed to confirm efficacy and applicability.

via ZME Science|

#colorectal-cancer #immunotherapy #msi-h

health1 year ago•3 min saved

Major Advances in Cancer Treatment Offer New Hope for Patients

A groundbreaking clinical trial shows that an immunotherapy drug, pembrolizumab, doubles the time head and neck cancer patients remain cancer-free, offering new hope for a difficult-to-treat cancer, with promising results suggesting it should be made available on the NHS.

via BBC|

#cancer #clinical-trial #head-and-neck-cancer

health1 year ago•3 min saved

Major Advances in Cancer Treatment Offer New Hope for Patients

A groundbreaking clinical trial shows that the immunotherapy drug pembrolizumab can double the time head and neck cancer patients remain cancer-free compared to standard treatments, offering new hope for improved outcomes in these patients.

via The Guardian|

#cancer #clinical-trial #head-and-neck-cancer

health1 year ago•3 min saved

Grandad Overcomes Stage 4 Cancer to Achieve Remission

Jeff Cook, diagnosed with stage 4 lung cancer in 2019, became cancer-free after two years of treatment with pembrolizumab, an immunotherapy drug, highlighting a significant medical breakthrough for advanced cancer treatment.

via KPVI|

#cancer-treatment #health #immunotherapy

health2 years ago•1 min saved

New Drug Jemperli Achieves 100% Success in Advanced Rectal Cancer Trial

Pembrolizumab, an immunotherapy drug also known as Keytruda, shows promising potential in treating bowel cancer by shrinking tumors and potentially eliminating the need for surgery and chemotherapy. This breakthrough, described as a "game-changer," enhances recovery rates and leverages the body's immune system to target cancer cells, offering fewer side effects compared to conventional treatments.

via Ynetnews|

#bowel-cancer #cancer #health

health2 years ago•2 min saved

Revolutionary Drug Melts Away Bowel Cancer Tumors, Triples Survival Rates

A clinical trial has shown that the immunotherapy drug pembrolizumab, which targets and blocks a specific protein on immune cells, can significantly increase the chances of curing bowel cancer and may replace the need for surgery. The trial, presented at the American Society of Clinical Oncology meeting, found that 59% of patients had no signs of cancer after treatment with pembrolizumab, compared to fewer than 5% with standard chemotherapy. Researchers are optimistic but note that further studies are needed to confirm long-term effectiveness.

via The Guardian|

#bowel-cancer #cancer-treatment #clinical-trial

health2 years ago•2 min saved

"Expanding the Reach of a Breast Cancer Drug: Potential to Benefit Thousands More Women"

Research suggests that the immunotherapy drug pembrolizumab, currently used for triple-negative breast cancer, could also benefit women with early-stage ER-positive HER2-negative breast cancer. A global trial showed a significant increase in the lack of cancer signs in tissue samples when pembrolizumab was used alongside chemotherapy, regardless of the patient's age or menopausal status. The findings, presented at the European Breast Cancer Conference, indicate the potential for more effective treatments for this common type of breast cancer, pending further research and regulatory approval. Additionally, a genetic test has been developed to identify how patients with triple-negative early-stage breast cancer will respond to immunotherapy drugs, allowing for more personalized treatment approaches.

via The Guardian|

#breast-cancer #health #immunotherapy

health3 years ago•6 min saved

Hope for Lung Cancer Patients: Potential Cure on the Horizon

Three new advances in lung cancer treatment were unveiled at the American Society for Clinical Oncology conference in Chicago. The most exciting was a high-tech drug called pembrolizumab, which boosts the immune system and significantly slows the return of the disease. The drug is currently only offered to NHS patients with advanced lung cancer whose disease has spread, but the treatment could now be offered to thousands more. Another drug, SKB264, has been dubbed a "warhead drug" as it can penetrate tumours, delivering a powerful "payload" of chemotherapy agents that attack cancer cells from the inside.

via Daily Mail|

#cancer-treatment #health #immunotherapy

health3 years ago•5 min saved

Advancements in Immunotherapy for Metastatic Brain Cancer

A phase 2 clinical trial of pembrolizumab has shown promising results, with 42% of patients with metastatic brain cancer benefiting from the treatment. Pembrolizumab, an immunotherapy, was tolerated and demonstrated clinical benefit in patients with brain metastases. While pembrolizumab showed promise, further studies are needed to identify potential biomarkers that can predict patient response to therapy.

via Neuroscience News|

#brain-cancer #clinical-trial #health

health3 years ago•0 min saved

"Combination of Moderna-Merck mRNA vaccine and melanoma drug shows cancer-fighting potential"

Moderna and Merck's personalized mRNA cancer vaccine, a neoantigen cancer vaccine, has shown clinical benefit in reducing the risk of relapse when combined with Merck's immunotherapy drug pembrolizumab, according to early experimental results. The vaccine offers hope for tailored cancer vaccines as a treatment.

via STAT|

#cancer #health #merck

medical3 years ago•7 min saved

"Combination Therapy Shows Promise in Advanced Biliary Tract Cancer Treatment"

Pembrolizumab, an immune checkpoint inhibitor, in combination with gemcitabine and cisplatin, has been found to improve overall survival in patients with advanced biliary tract cancer compared to gemcitabine and cisplatin alone, according to a phase 3 trial. The study involved 1,069 patients and found that the pembrolizumab group had a median overall survival of 12.7 months compared to 10.9 months in the placebo group. The combination therapy could be a new treatment option for patients with previously untreated metastatic or unresectable biliary tract cancer.

via The Lancet|

#biliary-tract-cancer #cisplatin #gemcitabine